What is linking COVID-19 and endothelial dysfunction? Updates on nanomedicine and bioengineering from the 2020 AHA Scientific Sessions
Authors:
Open Access
- 30 December 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 7 (3) , e2-e3
Abstract
The outbreak of the novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and declared as pandemic by the World Health Organization (WHO) on 11 March 2020, undoubtedly represents a global health threat worldwide. 1Keywords
Funding Information
- American Heart Association (AHA-20POST35211151)
- National Institutes of Health (R01-DK123259)
- National Institutes of Health (R01-HL146691)
- National Institutes of Health (R01-DK033823)
- National Institutes of Health (R00-DK107895)
- National Institutes of Health (R56-AG066431)
- National Institutes of Health (T32-HL144456)
This publication has 6 references indexed in Scilit:
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Therapy for Early COVID-19JAMA, 2020
- Abstract 14125: An in vitro Pulmonary Vascular Platform From Endothelialized Whole Lung ScaffoldsCirculation, 2020
- Abstract 221: Exosomal MicroRNAs Drive Tromboembolism in Covid-19Circulation, 2020
- COVID-19 is, in the end, an endothelial diseaseEuropean Heart Journal, 2020
- Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic EvidenceJournal of Clinical Medicine, 2020